TECVAYLI: payments to doctors
Payments that named TECVAYLI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.7M
- Providers
- 11,851
- Transactions
- 44,593
- Average per transaction
- $151
The per-transaction average — $151 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,851 providers the average total is $568, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $5,915,743 | 87.9% |
| Janssen Scientific Affairs, LLC | $296,163 | 4.4% |
| Janssen Global Services, LLC | $268,359 | 4.0% |
| Janssen Research & Development, LLC | $253,006 | 3.8% |